on Telomir Pharmaceuticals, Inc
Telomir Pharmaceuticals to Advance Age-Reversal Research at BIO 2025
Telomir Pharmaceuticals, Inc. is set to participate in the BIO International Convention 2025 in Boston. The company aims to explore strategic partnerships and discuss potential mergers and acquisitions. A key focus is the IND submission for its lead candidate, Telomir-1, a small molecule designed to elongate telomeres and combat biological aging, with human dosing planned for 2026.
Telomir is targeting rare diseases such as Werner's syndrome and Wilson's disease. Preclinical results show Telomir-1's effectiveness in various models, including age-related macular degeneration, type 2 diabetes, and aggressive prostate cancer. The company emphasizes its drug's cross-indication potential at the upcoming convention.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Telomir Pharmaceuticals, Inc news